← All drugs
Drug · FAERS side-effect profile with label screen

Isopropyl Alcohol side effects: what 33,603 FDA adverse event reports show

Isopropyl Alcohol · 1,192 reaction terms · 251,394 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

33,603 reports · 94% serious · 17,751 with death outcome · 51% female

openFDA FAERS counts, all years, deduplication not applied

Used for

first aid to help prevent the risk of infection in minor cuts, scrapes, and burns.

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Reporting / coding artifact 1Lab value / disease marker 10No label text to screen 29
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,152 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Grip strength124726.1
560.0–941.4ROR 728.8 · calibrated p 3e-15 ✓
317.1 EB05 273.0 · IC025 +6.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=124 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Ex-drug abuser13570.9
268.4–1,214.5ROR 571.1 · calibrated p 1e-11 ✓
206.8 EB05 128.6 · IC025 +3.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=13no trial arm names this drug
Blood ethanol18461.1
250.3–849.5ROR 461.4 · calibrated p 1e-11 ✓
206.4 EB05 138.1 · IC025 +4.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=18no trial arm names this drug
Anti-cyclic citrullinated peptide antibody278448.6
384.5–523.4ROR 452.3 · calibrated p 2e-13 ✓
255.2 EB05 231.0 · IC025 +7.3
3/3 methods agree
Lab value / disease markerserious n=278 · ♀ 100% (drug 51%) · 97% clinicianno trial arm names this drug
Lupus vulgaris481426.1
379.5–478.4ROR 432.3 · calibrated p 3e-13 ✓
249.6 EB05 231.4 · IC025 +7.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=481 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Postmortem blood drug level21339.8
199.4–578.9ROR 340.0 · calibrated p 6e-11 ✓
183.0 EB05 126.2 · IC025 +4.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=21no trial arm names this drug
Swollen joint count79296.2
226.5–387.3ROR 296.9 · calibrated p 2e-11 ✓
191.0 EB05 158.2 · IC025 +6.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=79 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Subcutaneous drug absorption impaired174293.9
245.4–352.0ROR 295.4 · calibrated p 2e-11 ✓
194.9 EB05 171.8 · IC025 +6.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=174 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Alcohol interaction569258.0
234.1–284.4ROR 262.4 · calibrated p 4e-11 ✓
180.9 EB05 168.8 · IC025 +7.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=505no trial arm names this drug
Deep vein thrombosis postoperative558249.0
225.8–274.5ROR 253.1 · calibrated p 5e-11 ✓
176.4 EB05 164.5 · IC025 +7.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=558 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Alcohol test positive13235.1
124.1–445.4ROR 235.2 · calibrated p 3e-9 ✓
136.6 EB05 85.0 · IC025 +3.6
3/3 methods agree
Lab value / disease markerserious n=13no trial arm names this drug
Adjustment disorder with depressed mood547233.1
211.3–257.0ROR 236.9 · calibrated p 9e-11 ✓
168.3 EB05 156.8 · IC025 +7.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=547 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Victim of crime319230.7
203.0–262.3ROR 232.9 · calibrated p 1e-10 ✓
166.4 EB05 151.6 · IC025 +6.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=319 · ♀ 92% (drug 51%) · 95% clinicianno trial arm names this drug
Swollen joint count increased829226.5
209.3–245.1ROR 232.2 · calibrated p 1e-10 ✓
165.2 EB05 156.0 · IC025 +7.1
3/3 methods agree
Lab value / disease markerserious n=829 · ♀ 100% (drug 51%) · 98% clinicianno trial arm names this drug
Rheumatic fever1,131218.6
204.4–233.7ROR 226.2 · calibrated p 1e-10 ✓
161.1 EB05 153.4 · IC025 +7.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=1,131 · ♀ 100% (drug 51%) · 95% clinicianno trial arm names this drug
C-reactive protein231213.6
183.9–248.0ROR 215.0 · calibrated p 3e-10 ✓
156.7 EB05 140.5 · IC025 +6.7
3/3 methods agree
Lab value / disease markerserious n=231 · ♀ 100% (drug 51%) · 98% clinicianno trial arm names this drug
Postmortem blood drug level abnormal36203.1
139.3–295.9ROR 203.3 · calibrated p 1e-9 ✓
141.6 EB05 106.8 · IC025 +5.1
3/3 methods agree
Lab value / disease markerserious n=36no trial arm names this drug
Dislocation of vertebra534197.5
179.3–217.6ROR 200.7 · calibrated p 4e-10 ✓
149.0 EB05 138.7 · IC025 +6.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=534 · ♀ 100% (drug 51%) · 95% clinicianno trial arm names this drug
Facet joint syndrome754196.6
181.2–213.2ROR 201.1 · calibrated p 4e-10 ✓
148.6 EB05 140.0 · IC025 +7.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=754 · ♀ 100% (drug 51%) · 92% clinicianno trial arm names this drug
Chemical submission58191.7
142.8–257.4ROR 192.0 · calibrated p 1e-9 ✓
139.7 EB05 112.1 · IC025 +5.6
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=58 · ♀ 88% (drug 51%) · 100% clinicianno trial arm names this drug
X-ray abnormal414188.8
169.2–210.7ROR 191.2 · calibrated p 6e-10 ✓
143.7 EB05 132.5 · IC025 +6.8
3/3 methods agree
Lab value / disease markerserious n=414 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Hepatic enzyme32185.6
125.0–275.6ROR 185.8 · calibrated p 3e-9 ✓
131.7 EB05 97.7 · IC025 +4.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=32 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Behavioural addiction14179.3
98.9–325.2ROR 179.4 · calibrated p 2e-8 ✓
117.2 EB05 74.2 · IC025 +3.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=14no trial arm names this drug
Acquired porphyria15167.7
94.7–296.7ROR 167.8 · calibrated p 2e-8 ✓
113.3 EB05 72.9 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=15no trial arm names this drug
Retinitis338158.6
140.8–178.7ROR 160.2 · calibrated p 3e-9 ✓
125.4 EB05 114.6 · IC025 +6.6
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=338 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Duodenal ulcer perforation1,394146.5
138.3–155.1ROR 152.8 · calibrated p 4e-9 ✓
118.3 EB05 113.2 · IC025 +6.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 72.7 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Alcohol abuse510145.8
132.5–160.5ROR 148.1 · calibrated p 5e-9 ✓
117.6 EB05 109.2 · IC025 +6.6
3/3 methods agree
Reporting / coding artifactserious n=434 · ♀ 29% (drug 51%)no trial arm names this drug
Foetal alcohol syndrome18135.0
81.0–224.8ROR 135.0 · calibrated p 7e-8 ✓
99.4 EB05 66.5 · IC025 +4.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=18no trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive1,232131.0
123.3–139.2ROR 135.9 · calibrated p 1e-8 ✓
108.0 EB05 103.0 · IC025 +6.6
3/3 methods agree
Lab value / disease markerserious PRR 66.6 · ♀ 100% (drug 51%) · 95% clinicianno trial arm names this drug
Rheumatoid factor positive980127.8
119.4–136.8ROR 131.6 · calibrated p 1e-8 ✓
105.8 EB05 100.3 · IC025 +6.5
3/3 methods agree
Lab value / disease markerserious n=980 · ♀ 100% (drug 51%) · 97% clinicianno trial arm names this drug
Alcohol poisoning441124.5
112.4–137.8ROR 126.1 · calibrated p 2e-8 ✓
103.2 EB05 95.4 · IC025 +6.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=432no trial arm names this drug
Porphyria acute222119.6
103.6–138.1ROR 120.4 · calibrated p 3e-8 ✓
99.5 EB05 89.0 · IC025 +6.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=222 · ♀ 100% (drug 51%) · 95% clinicianno trial arm names this drug
Muscle injury1,293116.8
110.1–123.8ROR 121.4 · calibrated p 3e-8 ✓
98.2 EB05 93.7 · IC025 +6.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 65.4 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Blood alcohol increased119110.9
91.2–134.7ROR 111.2 · calibrated p 7e-8 ✓
92.7 EB05 79.6 · IC025 +5.8
3/3 methods agree
Lab value / disease markerserious n=114no trial arm names this drug
Helicobacter infection1,507108.3
102.6–114.3ROR 113.3 · calibrated p 4e-8 ✓
92.1 EB05 88.3 · IC025 +6.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 59.9 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Folliculitis1,478104.2
98.8–110.0ROR 109.0 · calibrated p 6e-8 ✓
89.2 EB05 85.4 · IC025 +6.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 64.4 · ♀ 100% (drug 51%) · 96% clinicianno trial arm names this drug
Sleep disorder due to general medical condition, insomnia type905102.1
95.2–109.4ROR 104.9 · calibrated p 8e-8 ✓
87.5 EB05 82.9 · IC025 +6.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=903 · ♀ 100% (drug 51%) · 97% clinicianno trial arm names this drug
Substance use disorder41898.2
88.6–108.8ROR 99.4 · calibrated p 1e-7 ✓
84.5 EB05 77.9 · IC025 +6.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=418 · ♀ 29% (drug 51%) · 93% clinicianno trial arm names this drug
Blood ethanol increased3097.1
66.1–142.7ROR 97.2 · calibrated p 4e-7 ✓
79.9 EB05 58.6 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious n=30 · 100% clinicianno trial arm names this drug
Peripheral venous disease53496.3
88.0–105.5ROR 97.9 · calibrated p 1e-7 ✓
83.2 EB05 77.4 · IC025 +6.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=534 · ♀ 100% (drug 51%) · 93% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality7,41519.419.0–19.8signal
Liver injury2,7485.75.5–5.9signal
Interstitial lung disease7114.74.3–5.0signal
Rhabdomyolysis / myopathy5254.13.7–4.4signal
Depression1,3653.02.9–3.2signal
Hyperglycaemia / diabetes1,6142.92.8–3.1signal
Dependence / withdrawal1,3662.92.7–3.0signal
Pancreatitis3402.62.4–2.9signal
Seizure6682.12.0–2.3raised
Serious infection2,1701.81.7–1.8raised
Arrhythmia / qt5251.71.6–1.8raised
Hypoglycaemia2521.61.5–1.9raised
Gi bleeding4121.41.3–1.5raised
Fall / fracture6661.11.0–1.2raised
Extrapyramidal1550.90.8–1.1no difference
Hyponatraemia1160.90.7–1.1no difference

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Isopropyl Alcohol only as a background or rescue medication (NCT03523962); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Toxicity to various agents6,02223.2
22.7–23.7ROR 28.0 · calibrated p 4e-4 ✓
22.4 EB05 21.9 · IC025 +4.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 17.7 · serious PRR 14.1 · 92% clinicianno trial arm names this drug
Completed suicide (death by suicide)5,45943.3
42.2–44.4ROR 51.5 · calibrated p 1e-5 ✓
40.5 EB05 39.6 · IC025 +5.3
3/3 methods agree
Outcome field, not a reactionage-adj. PRR 26.3 · serious PRR 24.8 · 98% clinicianno trial arm names this drug
Drug abuse5,29542.1
41.1–43.2ROR 49.8 · calibrated p 1e-5 ✓
39.5 EB05 38.6 · IC025 +5.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 25.9 · serious PRR 24.4 · ♀ 28% (drug 51%) · 91% clinicianno trial arm names this drug
Overdose2,0385.9
5.7–6.2ROR 6.2 · calibrated p 0.136
5.9 EB05 5.7 · IC025 +2.5
3/3 methods agree
Reporting / coding artifactage-adj. PRR 6.2 · serious PRR 4.5no trial arm names this drug
Vomiting1,9062.5
2.4–2.7ROR 2.6 · calibrated p 0.757
2.5 EB05 2.4 · IC025 +1.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 1.8 · serious PRR 2.2 · ♀ 79% (drug 51%)no trial arm names this drug
Fatigue (tiredness)1,8831.5
1.4–1.6ROR 1.5 · calibrated p 0.671
1.5 EB05 1.5 · IC025 +0.5No label text to screen
label has no adverse-reaction text
age-adj. PRR 1.0 · serious PRR 1.7 · ♀ 89% (drug 51%)no trial arm names this drug
Confusional state (confusion)1,8767.3
7.0–7.6ROR 7.7 · calibrated p 0.075
7.2 EB05 6.9 · IC025 +2.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 5.4 · serious PRR 5.6 · ♀ 85% (drug 51%)no trial arm names this drug
Nausea1,8711.5
1.4–1.5ROR 1.5 · calibrated p 0.648
1.5 EB05 1.4 · IC025 +0.5No label text to screen
label has no adverse-reaction text
age-adj. PRR 1.0 · serious PRR 1.6 · ♀ 84% (drug 51%)no trial arm names this drug
Death1,8201.3
1.3–1.4ROR 1.3 · calibrated p 0.534
1.3 EB05 1.3 · IC025 +0.3Outcome field, not a reactionage-adj. PRR 2.1 · serious PRR 0.8 · 91% clinicianno trial arm names this drug
Pain1,8141.8
1.8–1.9ROR 1.9 · calibrated p 0.883
1.8 EB05 1.8 · IC025 +0.8No label text to screen
label has no adverse-reaction text
age-adj. PRR 1.3 · serious PRR 1.7 · ♀ 90% (drug 51%)no trial arm names this drug
Dyspnoea (shortness of breath)1,6881.9
1.8–2.0ROR 1.9 · calibrated p 0.894
1.9 EB05 1.8 · IC025 +0.8No label text to screen
label has no adverse-reaction text
age-adj. PRR 1.3 · serious PRR 1.5 · ♀ 87% (drug 51%)no trial arm names this drug
Rash1,6592.4
2.3–2.5ROR 2.5 · calibrated p 0.828
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 1.7 · serious PRR 3.1 · ♀ 95% (drug 51%) · 92% clinicianno trial arm names this drug
Drug ineffective (drug did not work)1,5650.7
0.7–0.8ROR 0.7 · calibrated p 0.145
0.7 EB05 0.7 · IC025 -0.5
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.7 · serious PRR 1.1 · ♀ 84% (drug 51%)no trial arm names this drug
Intentional overdose1,55615.6
14.8–16.4ROR 16.3 · calibrated p 0.005 ✓
15.2 EB05 14.6 · IC025 +3.8
3/3 methods agree
Reporting / coding artifactage-adj. PRR 9.7 · serious PRR 9.7no trial arm names this drug
Hepatic enzyme increased1,55114.6
13.9–15.3ROR 15.2 · calibrated p 0.007 ✓
14.2 EB05 13.7 · IC025 +3.7
3/3 methods agree
Lab value / disease markerage-adj. PRR 8.6 · serious PRR 12.5 · ♀ 97% (drug 51%) · 95% clinicianno trial arm names this drug

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Isopropyl Alcohol?

In FDA FAERS, the most frequently co-reported reaction terms for Isopropyl Alcohol are toxicity to various agents, vomiting, fatigue, confusional state, nausea, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Isopropyl Alcohol have an FDA boxed warning?

No. The FDA label retrieved for Isopropyl Alcohol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Isopropyl Alcohol causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.